Quartz·1 min read·medium
AstraZeneca stock sinks on reports of merger talks with Bristol Myers Squibb
✦AI Summary
AstraZeneca shares fell following reports of potential merger discussions with Bristol Myers Squibb. A deal between the two pharmaceutical giants could result in a combined entity valued at approximately $400 billion.
A combination of the two pharmaceutical companies could create an entity valued at nearly $400 billion, according to the Financial Times
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in